ERBB2 and breast carcinoma: With the development of trastuzumab, a monoclonal antibody that binds to the extracellular domain of the HER2 receptor, pathologic complete response (pCR), invasive disease‐free survival (IDFS), and overall survival (OS) outcomes have drastically improved for women with HER2‐positive breast cancer.1, 2, 3